| Identification | Back Directory | [Name]
Avdoralimab | [CAS]
2226393-85-5 | [Synonyms]
Avdoralimab
Avdoralimab (anti-C5AR1)
Research Grade Avdoralimab (DHD47201) |
| Hazard Information | Back Directory | [Uses]
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research[1]. | [in vivo]
In mice with a knock in for human C5aR1 (HuC5aR1 KI mice), Avdoralimab blocks the infiltration of neutrophils and monocytes, prevents albumin release in broncho-alveolar lavage fluid (BALF) and limits C5a-induced acute lung injury (ALI) histopathological features[1]. | [References]
[1] Julien Carvelli, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020 Dec;588(7836):146-150. DOI:10.1038/s41586-020-2600-6 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|